Literature DB >> 1828695

Timing of deletion of autoreactive V beta 6+ cells and down-modulation of either CD4 or CD8 on phenotypically distinct CD4+8+ subsets of thymocytes expressing intermediate or high levels of T cell receptor.

P Hugo1, R L Boyd, G A Waanders, H T Petrie, R Scollay.   

Abstract

In this paper we describe a differentiation sequence amongst adult murine thymocytes which goes from CD4+8+3lo(low) to CD4+8+3int(intermediate) to CD4+8+3hi(high) and then to mature single positive CD3hi thymocytes. Phenotypic characterization of CD4+8+3int/hi cells for a number of other surface markers is consistent with them being in transition from CD4+8+3lo phenotype to mature phenotype. The same observation was made for sensitivity towards ionomycin-mediated apoptosis. In the thymus of Mls-1a mice, where autoreactive TCR-V beta 6+ cells are negatively selected, deletion of TCR-V beta 6+ cells was first detected in the CD4+8+3int subset, and was complete by the CD4+8+3hi stage, suggesting that up-regulation of the TCR/CD3 complex is required for deletion of Mls-1a autoreactive thymocytes. No sign of apoptosis was detected among any fresh thymocyte subsets suggesting that apoptotic cells are rapidly cleared from the thymus. The CD4+8+3int/CD4+8+3hi cells are therefore populations in transit from the typical cortical thymocytes to the mature T-cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1828695     DOI: 10.1093/intimm/3.3.265

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  11 in total

Review 1.  Are we really on the right TRAIL?

Authors:  Erika Cretney; Adam P Uldrich; Stuart P Berzins; Andreas Strasser; Dale I Godfrey; Mark J Smyth
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

2.  CD45 enhances positive selection and is expressed at a high level in large, cycling, positively selected CD4+CD8+ thymocytes.

Authors:  C J Ong; J P Dutz; D Chui; H S Teh; J D Marth
Journal:  Immunology       Date:  1997-05       Impact factor: 7.397

3.  Negative selection in the thymus includes semimature T cells.

Authors:  H Kishimoto; J Sprent
Journal:  J Exp Med       Date:  1997-01-20       Impact factor: 14.307

4.  Without peripheral interference, thymic deletion is mediated in a cohort of double-positive cells without classical activation.

Authors:  Yifan Zhan; Jared F Purton; Dale I Godfrey; Timothy J Cole; William R Heath; Andrew M Lew
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-21       Impact factor: 11.205

5.  The essential role of LAT in thymocyte development during transition from the double-positive to single-positive stage.

Authors:  Shudan Shen; Minghua Zhu; Jasmine Lau; Mariana Chuck; Weiguo Zhang
Journal:  J Immunol       Date:  2009-05-01       Impact factor: 5.422

6.  Thymocyte development in major histocompatibility complex-deficient mice: evidence for stochastic commitment to the CD4 and CD8 lineages.

Authors:  A L Crump; M J Grusby; L H Glimcher; H Cantor
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-15       Impact factor: 11.205

7.  A special repertoire of alpha:beta T cells in neonatal mice.

Authors:  M Bogue; S Candéias; C Benoist; D Mathis
Journal:  EMBO J       Date:  1991-12       Impact factor: 11.598

8.  Molecular basis and outcomes of atypical haemolytic uraemic syndrome in Czech children.

Authors:  Šárka Štolbová; Martin Bezdíčka; Tomas Seeman; Zoltán Prohászka; Dorottya Csuka; Ingrid Hrachovinová; Jan Burkert; Naděžda Šimánková; Štěpánka Průhová; Jakub Zieg
Journal:  Eur J Pediatr       Date:  2020-05-18       Impact factor: 3.183

9.  Mixed typical and atypical hemolytic uremic syndrome in a kidney transplant patient.

Authors:  Mattia Rossi; Giuseppina Pessolano; Chiara Caletti; Vincenzo De Biase; Giovanni Gambaro
Journal:  J Nephrol       Date:  2021-07-05       Impact factor: 3.902

10.  Studies on T cell maturation on defined thymic stromal cell populations in vitro.

Authors:  E J Jenkinson; G Anderson; J J Owen
Journal:  J Exp Med       Date:  1992-09-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.